The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.275
Bid: 4.15
Ask: 4.40
Change: -0.025 (-0.58%)
Spread: 0.25 (6.024%)
Open: 4.30
High: 4.325
Low: 4.275
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small Cap Virtual Investor Conference

28 Nov 2023 07:00

RNS Number : 8894U
Eden Research plc
28 November 2023
 

 

Eden Research to Present at the Small Cap Virtual Investor Conference November 30, 2023

 

Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com

 

Didcot, Oxfordshire, November 28, 2023 -- Eden Research plc (AIM:EDEN | OTCQB: EDNSF), based in Oxfordshire, UK, focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, today announced that Sean Smith, Chief Executive Officer, will present live at the Small Cap Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on November 30, 2023.

 

DATE: November 30, 2023

TIME: 09:30 - 10:00 ET | 14:30 - 15:00 GMT

LINK: https://bit.ly/46MMy8s

 

This will be a live, interactive online event where investors are invited to ask the company

questions in real-time. If attendees are not able to join the event live on the day of the

conference, an archived webcast will also be made available after the event.

 

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. 

 

Learn more about the event at www.virtualinvestorconferences.com.

 

Recent Company Highlights

 

? Launch of Ecovelex, Eden's third flagship sustainable crop protection product, in collaboration with Corteva

? Successful fundraise of £9.9 (c. $12.5) million to accelerate the company's growth

? Various regulatory approvals across key regions including the US and Central Europe

? Recent regulatory approvals have converted to 55% rise in product sales in FY 2022.

? Over 140 field trials run in 2023 with potential distribution partners for an insecticide, Eden's next crop protection product

 

###

 

About Eden Research plc

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz? is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit: www.edenresearch.com.

 

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

 

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

 

 

CONTACTS:

 

Hawthorn Advisors (PR advisor to Eden Research)

eden@hawthornadvisors.com

+44 (0)20 3745 4960

 

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFIFSELDLTFIV
Date   Source Headline
1st Sep 20157:03 amRNSProduct approval in Greece
24th Aug 20157:00 amRNSTerpeneTech Licence Agreement and Investment
25th Jun 20157:00 amRNSActive substances approved for MRL exemption
10th Jun 201512:25 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
27th May 20157:00 amRNSDirector/PDMR Shareholding
26th May 20157:01 amRNSEU Product Authorisation
20th May 201510:07 amRNSPosting of Annual Report & Notice of AGM
20th May 20157:00 amRNSAgreement with Sipcam covering new products
11th May 20157:00 amRNSAppointment of a Director and Share Options
13th Apr 20157:00 amRNSOption agreement with Taminco
30th Mar 20157:00 amRNSFinal Results
18th Feb 201511:08 amRNSDeath of a Director
2nd Feb 20157:00 amRNSGrant of Patent in South Korea
8th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSProgress on EU zone approval
1st Dec 20147:00 amRNSLicence Agreement with SUMIAGRO
28th Nov 20147:00 amRNSConversion of all outstanding debt
21st Nov 20143:26 pmRNSPlacing to raise £750,000
21st Nov 20147:00 amRNSLicence Agreement with SIPCAM
29th Sep 20147:00 amRNSSuccessful trials in Greece to combat Botrytis
29th Sep 20147:00 amRNSHalf Yearly Report
18th Aug 20147:00 amRNSDirectorate changes & share options
11th Aug 20147:00 amRNSEvaluation agreement for nematicide
1st Jul 20147:00 amRNSNotice of Decision of Patent in South Korea
26th Jun 201412:37 pmRNSAGM Statement
6th Jun 201410:46 amRNSPosting of Annual Report & Notice of AGM
6th Jun 20147:00 amRNSExtension of TerpeneTech licence agreement
30th May 20147:00 amRNSPreliminary Results
15th May 20147:00 amRNSNotice of Allowance for Mexican patent
8th May 20145:12 pmRNSDeath of a Director
24th Apr 20147:00 amRNSNotice of Allowance for Canada patent
22nd Apr 20147:01 amRNSFirst commercial products launched with Eden tech
10th Mar 20147:00 amRNSFurther progress in EU product approval
13th Jan 20147:00 amRNSData Access Licence and Royalty Agreement
19th Nov 201312:54 pmRNSHolding(s) in Company
18th Nov 201311:48 amRNSHolding(s) in Company
9th Oct 20137:00 amRNSNotice of Allowance from ARIPO
24th Sep 20137:00 amRNSHalf Yearly Report
28th Aug 20137:00 amRNSNotice of Allowance
27th Aug 201310:33 amRNSHolding(s) in Company
24th Jun 20131:39 pmRNSResult of AGM
24th Jun 20137:00 amRNSAGM Statement
5th Jun 20137:00 amRNSLicence agreement for head lice treatment
31st May 20135:22 pmRNSPosting of Annual Report & Notice of AGM
31st May 20137:08 amRNSPreliminary Results
20th May 20137:00 amRNSEU approval for active substances
25th Apr 20137:00 amRNSNotice of Allowance from ARIPO
16th Apr 201311:40 amRNSHolding(s) in Company
15th Mar 20137:00 amRNSMaster Encapsulation Patent Granted in Europe

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.